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Abstract
Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in the production of prostaglandins,
potent mediators of inflammation. Chronic inflammation plays an important role in the development
and progression of colorectal cancer. Aspirin inhibits COX-2 activity and lowers the risk of colorectal
adenomas and cancer. We investigated whether common genetic variation in COX-2 influenced risk
of colorectal adenoma recurrence among 979 participants in the Aspirin/Folate Polyp Prevention
Study who were randomly assigned to placebo or aspirin and followed for 3 years for the occurrence
of new adenomas. Of these participants, 44.2% developed at least one new adenoma during follow-
up. Adjusted relative risks (RRs) and 95% confidence intervals (CIs) were calculated to test the
association between genetic variation at six COX-2 single nucleotide polymorphisms (SNPs) and
adenoma occurrence and interaction with aspirin treatment. Two SNPs were significantly associated
with increased adenoma recurrence: for rs5277 homozygous carriers of the minor C allele had a 51%
increased risk compared to GG homozygotes (RR=1.51, 95% CI=1.01–2.25), and for rs4648310
heterozygous carriers of the minor G allele had a 37% increased risk compared to AA homozygotes
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(RR=1.37, 95% CI=1.05–1.79). (There were no minor allele homozygotes.) In stratified analyses,
there was suggestive evidence that rs4648319 modified the effect of aspirin. These results support
the hypothesis that that COX-2 plays a role in the etiology of colon cancer and may be a target for
aspirin chemoprevention and warrant further investigation in other colorectal adenoma and cancer
populations.
Introduction
Mounting evidence from experimental and observational studies supports the role of
inflammation in the development and progression of cancer, including colorectal cancer (1–
4). Cyclooxygenase-2 (COX-2), also known as prostaglandin G/H synthase-2 (PTGS-2), is an
inducible enzyme which catalyzes the rate-limiting step in the production of prostaglandins
and plays a key role in inflammation (5). COX-2 may also have an important role in the etiology
of colorectal and other cancers (6,7). It is upregulated in colorectal adenomas and cancer;
approximately half of all colorectal adenomas and more than 85% of colorectal cancers have
elevated levels of COX-2 (8–11). Increased COX-2 levels have been shown to correlate with
later stage, larger tumor size, presence of lymphatic metastases, and risk of recurrence and
poorer survival in human colorectal cancers (12–15). Expression and activity of COX-2 is
thought to contribute to tumor promotion and carcinogenesis through stimulation of cell
proliferation, inhibition of apoptosis, and promotion of angiogenesis and invasiveness (16,
17).
Important additional evidence supporting a role for COX-2 in the inflammation-colon
carcinogenesis pathway comes from observational studies and randomized clinical trials
demonstrating that nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin (18–
21) and selective COX-2 inhibitors (22–25), reduce the risk of colorectal adenoma and cancer.
Notably, aspirin use preferentially reduced the risk of colorectal cancers that overexpressed
COX-2, suggesting that the anticancer benefit of aspirin is mediated, at least in part, by effects
on COX-2 (26).
Twin studies indicate that heritable factors play a relatively large role in the causation of
sporadic colorectal cancer, an estimated 35% (27). Although knowledge about the genetic
factors that contribute to sporadic cancer is limited, several genome-wide association studies
have been published with replicated findings (28) (29). Genetic variation in the COX-2 gene
may alter enzyme expression or activity, thereby altering the production of prostaglandins and
potentially modulating an individual's inflammatory response and risk of colorectal cancer. In
addition, it is possible that polymorphisms in the COX-2 gene could alter an individual's
response to NSAIDs, and thus modify the chemopreventive effect of NSAIDs in colorectal
neoplasia (30).
Associations of polymorphisms in the COX-2 gene with colorectal adenomas and colorectal
cancer have recently been investigated (31–39), including analyses of interactions with aspirin
use (33,40–44), and the findings have been mixed. This existing literature is limited by
incomplete analysis of genetic variation in the COX-2 gene, small sample sizes and inconsistent
and poorly defined measurement of NSAID use. Further investigation into the association
between COX-2 genotype and colorectal neoplasia and interaction with NSAID use is needed
to clarify the role of genetic variation in COX-2 and may identify individuals who would benefit
the most from the use of NSAIDs in the prevention of colon cancer.
The present analysis was undertaken to investigate the impact of COX-2 polymorphisms on
risk of colorectal adenoma recurrence and the interaction between COX-2 genotype and aspirin
treatment among participants at high risk of adenoma recurrence who were randomly assigned
to placebo or aspirin in a large adenoma chemoprevention trial (19). By providing a more
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comprehensive analysis of the genetic variation in a relatively large population with a precisely
defined and randomized exposure to aspirin treatment, this investigation overcomes many of
the limitations of the existing literature.
Materials and Methods
Study Design and Population
We conducted a cohort analysis of the association between COX-2 genotypes and colorectal
adenoma recurrence among participants from the Aspirin/Folate Polyp Prevention Study (19,
45). Eligible participants were aged 21–80 with no history of colorectal cancer or any familial
colorectal cancer syndrome but with a recent history of a histologically confirmed colorectal
adenoma and a complete colonoscopy within three months before enrollment with no
remaining colorectal polyps. At enrollment, data was collected on potential risk factors for
colorectal cancer, including cigarette smoking, alcohol use and body mass index (BMI). After
a run-in period during which compliance with study procedure was assessed, a total of 1121
subjects were randomized to aspirin treatment (placebo, 81 mg or 325 mg daily) and folic acid
treatment (placebo or 1 mg daily) in a three-by-two factorial design and followed until a
subsequent colonoscopy was performed. The study was completed by 1084 participants (96.7%
of 1121 randomized) who had a follow-up colonoscopy at least one year after randomization
(mean intervention period ± standard deviation, 32.7 ± 3.8 months). Of these participants, 979
(90.3%) had DNA available for genotyping and are included in the analyses presented here.
This work was approved by the institutional review boards at all participating institutions,
including the National Cancer Institute, where genotyping was performed, and each of the
collaborating clinical centers. All subjects provided written informed consent.
Genotyping
Genomic DNA was isolated from whole blood cells using proteinase K digestion and phenol-
chloroform extraction. The COX-2 polymorphisms were genotyped with the 5'nuclease
TaqMan allelic discrimination assay using the ABI 7900 Sequence Detection System (Applied
Biosystems, Foster City, CA) as previously described (46). Briefly, oligonucleotide probes
were labeled with two fluorescent dyes, FAM and VIC, to distinguish between the two alleles
of each biallelic SNP. All assays were designed and developed using Assays-by-Design
(Applied Biosystems). All primers and probes were synthesized by Applied Biosystems. Each
384-well assay contained internal quality controls of homozygous wild-type, heterozygous,
and homozygous variant alleles for the respective polymorphisms along with no template
controls. Assays were set up in 384-well plates using 2.5 μl of the 2X TaqMan Universal Master
Mix (no AmpErase UNG) including forward/reverse primers and FAM/VIC-labeled probes
and 2–5 ng of DNA in a final volume of 5 μl. The thermal cycling conditions for the ABI
7900HT Sequence Detector included an initial setting of 95°C for 5 minutes followed by 40
cycles each of 92°C for 15 seconds and 60° C for 1 minute. Data output was processed and
downloaded electronically into the analysis program. The SDS 2.1 analysis software (Applied
Biosystems) was used to determine the genotype calls.
Eight haplotype tagging SNPs were chosen for genotyping based upon their minor allele
frequencies (MAFs) of 9% and above as detailed at the SeattleSNPs web site1: rs689466 (798),
rs20417 (1228), rs2745557 (2331), rs5277 (3355), rs20432 (5229), rs5275 (8494), rs2206593
(9123), and rs4648310 (11027). The numbers in parentheses refer to positions in the gene
(Genbank entry AY382629). A total of 19 (2%) blinded replicates were included in the set of
DNAs genotyped. As the concordance rate for rs689466 was very low (47%), this SNP was
dropped from the analysis. For the remaining seven SNPs the concordance rate was 100% and
1http://pga.gs.washington.edu/data/ptgs2/
Barry et al. Page 3













the completion rates ranged from 96 to 99.6 %. Observed and expected genotype counts among
controls (participants with no adenoma recurrence) were evaluated for Hardy-Weinberg
equilibrium (HWE) by a one degree of freedom χ2 test. One SNP, rs2206593, deviated
substantially from HWE (P<0.0001), with fewer heterozygotes than expected. In addition, the
MAF observed (0.34) was much higher than expected (0.03–0.10) in populations of European
ancestry (CEU) based on information in the NCBI database (dbSNP), indicating likely
genotyping error. Thus, rs2206593 was also dropped from the analysis. The remaining six
SNPs, which all exhibited HWE and allele frequencies similar to expected from available
databases, were included in the analyses (see Table 1). Gene coverage was determined using
the tagger application in the Haploview software program (47) by downloading CEU genotypes
from the HAPMAP database and measuring the % of common variants (defined as SNP MAF
>0.03) tagged (r2 > 0.8) by genotyping these six SNPs.
Race and Ethnicity
At enrollment, subjects were asked to complete a questionnaire in which they identified their
“race or ethnic background” by selecting one of the following: (1) “white, not of Hispanic
origin”, (2) “black, not of Hispanic origin”, (3) “Hispanic”, (4) “American Indian or Alaskan
Native”, (5) “Asian or Pacific Islander”, (6) “other”, (7) “uncertain”. There were no responses
of (7) “uncertain”. In Table 1, categories 4 and 6 are not shown because to the very small
numbers in these two groups. For multivariable analyses, categories 2–6 were combined into
one group to create a dichotomous variable.
Statistical Methods
Comparisons of subject characteristics by adenoma recurrence status were performed by
Pearson Chi-square tests for categorical variables and two sample t-tests for continuous
variables. The principal outcome measured during the trial was the occurrence of one or more
adenomas during randomized treatment; however, we also evaluated the occurrence of one or
more advanced lesions (defined as tubulovillous or villous adenomas, adenomas ≥1 cm in
diameter, adenomas with severe dysplasia, and invasive cancer). Risk ratios were calculated
using an overdispersed generalized linear regression model for the Poisson distribution as an
approximation to the bionomial family (48). Relative risks (RRs) and 95% confidence intervals
(95% CIs) were used to estimate the association between COX-2 genotype and risk of adenoma
recurrence. Unadjusted, minimally adjusted (for age, gender, and race) and maximally adjusted
(for age, gender, race, BMI, smoking status, alcohol use, clinical center, follow-up time, aspirin
treatment and folate treatment) RRs were calculated. Results for crude and fully adjusted
models were nearly identical to the minimally adjusted RRs that are reported in the tables.
Homozygosity for the most frequent genotype was set as the referent category and RRs were
calculated by comparing the heterozygotes to the referent and the minor allele homozygotes
to the referent using indicator variables (i.e. an unrestricted genetic inheritance mode). Where
appropriate (i.e. rs5277) a recessive inheritance mode was also assessed by comparing minor
allele homozygotes to a referent group including major allele homozygotes and heterozygotes.
Phased haplotypes pairs and probabilities were estimated using Powermarker V3.25 (49) using
the EM algorithm (50). Generalized linear regression was used to estimate haplotype
association with risk of adenoma recurrence taking haplotype uncertainty (probabilities) into
account. The haplotype was modeled as a continuous variable where the number of copies of
each allele was multiplied by its probability to obtain a continuous variable which was used as
the predictor variable. The most common haplotype was used as the reference and omitted
from the model. For each haplotype, the model provides an estimate of the risk associated with
each additional copy of the specified haplotype. The most frequent haplotypes (with
frequencies above 2%) were analyzed individually and the remaining “rare” haplotypes were
pooled.
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We also evaluated whether aspirin treatment or participant characteristics interacted with
COX-2 genotypes to modify associations with adenoma risk using interaction terms in the
regression models and Wald tests. The following participant characteristics were considered:
gender, age (above versus below median), BMI (< 25, 25 to < 30, ≥30 kg/m2), current alcohol
use (drinker versus non-drinker) and smoking status (current smoker versus non-smoker). To
increase power for tests of effect modification, we combined the heterozygotes and the minor
allele homozygotes into one category and compared it to the referent group of the major allele
homozygotes. Stratified analyses were used to obtain stratum specific estimates of risk and
confidence intervals. Effect modification was only assessed for the risk of any adenoma
because of the small numbers of advanced lesions.
Analyses of study treatment with aspirin or folate were conducted according to the intention-
to-treat principle. Two-sided P values < 0.05 were considered statistically significant. We did
not adjust for multiple testing as per convention in epidemiologic studies testing a priori
defined hypotheses. Stata (version 9) was used for all analyses.
Results
Participant Characteristics and Gene Frequencies
Demographics and other selected characteristics of the subset of participants with DNA
available for COX-2 genotyping are presented in Table 2. Among the 979 participants, 433
(44.2 %) had a recurrence of one or more colorectal adenoma during follow-up. Age, gender
and race were all associated with risk of adenoma recurrence: individuals with at least one
colorectal adenoma recurrence during follow-up were slightly older than those who did not
have a recurrence (59.1 and 56.4 years respectively, p<0.001), males were at greater risk
compared to females (p=0.004), and Hispanics and Asians appeared to be at reduced risk
compared to Caucasians (p=0.063 and 0.052, respectively). In addition, cigarette smoking,
body mass index (BMI) and alcohol use were associated with risk of adenoma recurrence:
current smokers were at greater risk compared to non-smokers (p = 0.001), individuals with a
BMI between 25 and < 30 kg/m2 or ≥30 kg/m2 were at greater risk than those with a BMI <25
kg/m2 (p = 0.018 and 0.005 , respectively), and those who consumed alcoholic drinks were at
greater risk than non-drinkers (p = 0.008) As observed in the full analysis of the trial (19,45),
individuals who were randomized to 81 mg/day of aspirin treatment were less likely to have a
recurrence compared to those randomized to the placebo arm (p=0.017), whereas 325 mg/day
aspirin (p=0.86) and folate had no significant effect (p=0.40). Finally, the mean follow-up time
did not differ according to adenoma recurrence status (p=0.32).
MAFs and gene locations for the six COX-2 SNPs that were included in this analysis are shown
in Table 1. All six SNPs were in HWE among controls (participants with no adenoma
recurrence) and genotype frequencies were similar to those expected for a population with
predominantly European ancestry.2 Notably, the gene frequencies for several of the SNPs
(rs5277, rs20432, rs5275) varied statistically significantly by self-reported race and ethnicity
(Table 1). Due to linkage disequilibrium, genotyping these six SNPs captured approximately
80% of the common genetic variants (SNPS with MAF > 0.03) in the COX-2 gene.
Association of COX-2 Genotypes and Haplotypes with Risk of Colorectal Adenoma
Recurrence
We investigated whether any of the six COX-2 SNPs were associated with the recurrence of
any adenoma or with advanced lesions (Table 3). Two COX-2 SNPs were associated with a
statistically significant increased risk of adenoma recurrence: rs5277 and rs4648310. For
2http://www.hapmap.org
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rs5277, minor allele homozygotes (CC genotype) had a 49% increased risk of any adenoma
compared to the common GG genotype (unadjusted absolute risk 63.6% vs. 46.7%, adjusted
RR = 1.49, 95% CI = 1.00–2.23). Similar results were seen when the analysis was restricted
to Caucasians only (adjusted RR = 1.61, 95% CI = 1.08–2.39). The pattern seen with rs5277
was indicative of a recessive inheritance mode, since heterozygotes did not have an increased
risk, and was statistically significant when analyzed as such (adjusted RR = 1.48, 95% CI =
1.00–2.21, P = 0.05, not shown). For rs4648310 there were no minor allele homozygotes,
however, the heterozygotes (AG genotype) had a statistically significant 35% increased risk
of any adenoma compared to those with the common AA genotype (unadjusted absolute risk
60.4% vs. 43.3%, adjusted RR = 1.35, 95% CI = 1.03–1.77). There was also a non-significant
40% increase risk of an advanced lesion among these heterozygotes (adjusted RR = 1.40, 95%
CI = 0.67–2.91). Similar results were seen when the analysis was restricted to Caucasians only
for any adenoma (adjusted RR = 1.34, 95% CI = 1.01–1.76) or advanced lesions (adjusted RR
= 1.42, 95% CI = 0.68–2.97). There was no evidence for heterogeneity between the results for
advanced vs. non-advanced adenomas for any of the COX-2 genotypes analyzed (data not
shown). In addition, in stratified analyses, there was no evidence for interaction between any
COX-2 genotype and subject characteristics, including gender, age, BMI, alcohol use or
smoking status (data not shown).
The r2 correlation between the two SNPs associated with risk (rs5277 and rs4648310) was
0.16 indicating that they are not in strong linkage disequilibrium. In addition, when both SNPs
were included in the same regression model their associations with risk (RRs) remained
substantially similar to those seen in the single SNP models (in Table 3) although the
associations were no longer statistically significant due to reduced power (data not shown).
Haplotype analysis revealed six common haplotypes with a frequency above 2% (Table 4).
The 5 most common haplotypes were not associated with risk of adenoma recurrence.
However, the 6th most common haplotype, with a frequency of 2.7%, was associated with a
statistically significant 37% increased risk per copy of the haplotype relative to the most
common haplotype (adjusted RR = 1.37 , 95% CI = 1.03–1.82). Notably, this haplotype
contained variant alleles at rs5277 and rs4648310, both of which were associated with
deleterious effects at the genotype level (see Table 3). For advanced adenomas (data not
shown), there was an increased risk of similar magnitude that was not statistically significant
(adjusted RR = 1.36, 95% CI = 0.62–2.96).
Interaction with Aspirin Treatment
Next, we evaluated whether there was evidence for an interaction between any COX-2
genotype and aspirin treatment on risk of adenoma recurrence (Table 5). There was suggestive
evidence for an interaction between rs4648310 genotype and 81 mg of aspirin treatment. As
observed in the overall population, 81 mg of aspirin treatment daily was associated with a
protective effect among major allele homozygotes (AA genotype) (adjusted RR = 0.76, 95%
CI = 0.63–0.91). However, 81 mg of aspirin was not protective among heterozygotes (AG
genotype): RR = 1.55 (95% CI = 0.98–2.46) compared to AA homozygotes given placebo
(Table 5) and RR = 1.26 (95% CI = 0.61–2.57) compared to AG heterozygotes given placebo
(not shown). This interaction did not reach statistical significance (P = 0.11) unless the placebo
and 325 mg aspirin groups were combined (P = 0.037, not shown). Similar results were obtained
when this analysis was restricted to Caucasians (not shown).
Discussion
In this analysis of a randomized aspirin trial, we investigated the impact of common COX-2
variants on risk of colorectal adenoma recurrence and aspirin chemoprevention. We observed
statistically significant increased risks of adenoma recurrence of 49% for the rs5277 CC
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genotype and 35% for the rs4648310 AG genotype relative to the homozygous wild type
genotypes. Notably, for each copy of a common haplotype containing both variant alleles there
was a statistically significant 37% increased risk of adenoma recurrence. In addition, there was
suggestive evidence that the protective effect of treatment with 81 mg/day aspirin on risk of
colorectal adenoma recurrence was modified by the rs4648310 genotype because the aspirin
protective effect was not seen among AG heterozygotes.
A recent review summarized the associations of COX-2 polymorphisms with risk of colorectal
adenoma and cancer (51). Although results on 17 COX-2 polymorphisms from 14 studies were
reviewed, the ability to reach conclusions was hampered by small sample sizes and other
significant limitations in the studies and the analyses (51). Four of the COX-2 polymorphisms
that we examined in the current study have been investigated previously for associations with
colorectal adenoma, including rs20417, rs20432 and rs5275 (for which we observed no
association) and rs5277 (for which we observed an increased risk). For rs20417, pooled
analysis showed no association with adenomas, but a trend towards increased risk for cancer
that reached statistical significance only among Asians (51). For rs5275, pooled analyses
showed a non-significant trend towards a protective effect for adenomas and no association
with cancer (51). For rs20432, no associations were found for adenomas or cancer (51). For
rs5277, a synonymous SNP in exon 3, we found a statistically significant increased adenoma
risk, whereas in the pooled analysis (51) there was a non-significant trends towards a
reduced adenoma risk based on two previous studies (42,44) and towards an increased cancer
risk cancer based on two previous studies(52) (34). Thus, our data regarding rs5277 appears
to be more consistent with the previous cancer data than the adenoma data. We also examined
two COX-2 polymorphisms not previously investigated: rs2745557 and rs4648310. We did
not detect an association for rs2745557 with adenoma risk. However, rs4648310, located in
the 3' untranslated region, was associated with an increased risk for any adenoma and a non-
significant increased risk for advanced adenoma.
Another recent review examined interactions of COX-2 polymorphisms with NSAID use in
preventing colorectal neoplasia (53). A total of 17 polymorphisms have been investigated
across six studies, but no statistically significant interactions have been reported, possibly due
to limited sample sizes (53). A borderline significant interaction was reported for rs20417
(40), but was not confirmed in a different study (42) or in the present analysis. In the current
study, we found suggestive evidence for an interaction of aspirin treatment with rs4648310,
which also had a main effect on adenoma risk. However, the power to detect interactions was
limited in the present analysis and it will be important to follow-up on this finding in other
populations because of the potential clinical implication for aspirin chemoprevention.
Nonetheless, at the population level, the impact will be limited due to the low frequency of the
variant allele. As discussed previously, aspirin is not thought to inhibit Cyclooxygenase-2 at
the doses used here; however, it may suppress the expression of COX-2 (19). Regardless, the
mechanism is not clear and this finding may be due to chance. Finally, it is worth noting that
aspirin's effects are likely to involve multiple pathways in addition to COX-2, including COX-1
and other non-COX mechanisms (54,55).
The functional effects of the two SNPs associated with adenoma risk, rs4648310 and rs5277,
are not yet known. In addition, it can not be determined from this investigation whether they
represent causative SNPs or whether they are simply markers in linkage disequilibrium with
unknown or unmeasured causative SNPs. However, based on their association with increased
risk, one possibility is that they may either cause or be associated with an increase in COX-2
activity or expression. Notably, rs4648310 was also recently associated with an increased risk
of aggressive prostate cancer, and this effect was modified by dietary omega-3 fatty acids
(56).
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There are several potential limitations to consider in the current analysis. The generalizability
of the results may be limited as the study was conducted on predominantly Caucasian
volunteers in a clinical trial with a prior history of adenoma. The endpoint of the study was
occurrence of new adenomas rather than colorectal cancer. In addition, we had limited power
to investigate risk of advanced adenomas, which were uncommon during follow-up (10% of
the population), and interactions with two levels of aspirin treatment. Finally, the associations
detected were modest and our findings may be due to chance. Nonetheless, there are several
important strengths associated with this study, including the relatively large sample size and
the prospective study design, which makes recall or selection bias unlikely. In addition, the
outcome (adenoma) was uniformly assessed by a single study pathologist who was blinded to
study treatment assignment. Importantly, exposure to aspirin was by randomized treatment
with excellent compliance and follow-up. Finally, our analysis encompassed approximately
80% of the common genetic variants in the gene.
In summary, we observed an increased risk of colorectal adenoma recurrence in association
with two variants (rs5277 and rs4648310) in the COX-2 gene as well as a possible interaction
between aspirin use and one of these variants (rs4648310). Although these results provide
support for the hypothesis that COX-2 plays a role in the etiology of colon cancer and may be
a target for aspirin chemoprevention, the associations were modest and may be due to chance.
Thus, it is important to interpret these results with caution and to replicate them in other
colorectal adenoma and cancer populations.
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Table 2
Selected characteristics of the study participants with COX-2 genotype data
Characteristic Total No Adenoma Recurrence Adenoma Recurrence p-value*
No. of subjects 979 (100) 546 (55.8) 433 (44.2)
Age at enrollment (mean ± SD),
years 57.6 ± 9.6 56.4 ± 9.7 59.1 ± 9.3 <0.001
Gender
Male, No. (%) 630 (64.4) 330 (60.4) 300 (69.3)
Female, No. (%) 349 (35.6) 216 (39.6) 133 (30.7) 0.004
Race and ethnicity, No. (%)
Caucasian 864 (88.3) 473 (86.6) 391 (90.3)
African American 45 (4.6) 22 (4.0) 23 (5.3) 0.44
Hispanic 45 (4.6) 31 (5.7) 14 (3.2) 0.063
Asian 18 (1.8) 14 (2.6) 4 (0.9) 0.052
Other 7 (0.7) 6 (1.1) 1 (0.2) 0.10
Body mass index (kg/m2), No. (%)
<25 309 (31.6) 193 (35.4) 116 (26.9)
25–30 455 (46.6) 245 (45.0) 210 (48.6) 0.018
≥30 213 (21.8) 107 (19.6) 106 (24.5) 0.005
Current cigarette smoker, No. (%)
No 841 (86.2) 487 (89.4) 354 (82.1)
Yes 135 (13.8) 58 (10.6) 77 (17.9) 0.001
Current alcohol use, No. (%)
No 293 (31.2) 181 (34.7) 112 (26.7)
Yes 647 (68.8) 340 (65.3) 307 (73.3) 0.008
Aspirin treatment group, No. (%)
Placebo 329 (33.6) 174 (31.9) 155 (35.8)
81 mg aspirin 330 (33.7) 205 (37.6) 125 (28.9) 0.017
325 mg aspirin 320 (32.7) 167 (30.6) 153 (35.3) 0.86
Folate treatment group, No. (%)
Placebo 449 (45.9) 258 (47.3) 191 (44.1)
1 mg folate 452 (46.2) 247 (45.2) 205 (47.3) 0.40
Not randomized to folate 78 (8.0) 41 (7.5) 37 (8.6) 0.42
Follow-up time (mean ± SD),
months 32.7 ± 3.5 32.6 ± 3.3 32.8 ± 3.8 0.32
*
Tests for comparison between group with no adenoma recurrence and group with adenoma recurrence using two sample t-test for continuous variables
and Pearson chi-square test for categorical variables.
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Table 4
Association of COX-2 haplotypes with risk of adenoma recurrence
COX-2 Haplotype* Haplotype Frequency (%) Occurrence/Total (%) RR† (95% CI) p-value‡
GCGTTA 32.11 262/631 (41.9%) 1.00 (referent)
GCGTCA 18.23 150/355 (42.3%) 0.99 (0.85–1.15) 0.86
GTGTTA 17.28 150/338 (44.4%) 1.01 (0.87–1.18) 0.86
CCGGCA 15.12 136/298 (45.6%) 1.08 (0.93–1.26) 0.33
GCCTTA 11.81 107/229 (46.7%) 1.08 (0.91–1.29) 0.36
GCCTTG 2.73 32/53 (60.4%) 1.37 (1.03–1.82) 0.03
Rare§ 2.71 27/48 (56.3%) 1.35 (1.01–1.80) 0.04
*
SNP order according to Table 2.
†
Adjusted for age, gender and race.
‡
Wald test for comparison to most frequent haplotype.
§
Combination of haplotypes with a frequency of less than 2%.
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